iDR26:
Navigating the Future
Brussels
Belgium
INTERNATIONAL DRUG REPURPOSING CONFERENCE
Join the leading international drug repurposing conference to explore the future of patient-centred medicines repurposing.
From rare diseases and AI-driven drug discovery, to policy, funding and community-led success stories, iDR26 brings together the global drug repurposing community to navigate the next chapter in maxmising patient benefit.
CONFERENCE STARTS IN:
Why Join This Event?
Join an international community of experts who are driving real-world change in drug repurposing. iDR26 offers an unparalleled opportunity to exchange insights, build partnerships, and explore how repurposing can deliver faster, more affordable treatments for patients worldwide.
Cutting-edge science
Explore AI-driven drug discovery, biosimilars, biologics, and emerging technologies transforming the drug repurposing pathway.
Community and collaboration
Connect with key stakeholders through interactive sessions, poster presentations, and networking opportunities designed to strengthen the global repurposing ecosystem.
Policy and access discussions
Engage with policy–makers, funders and regulatory experts to identify viable market routes and policy frameworks ensuring equitable access to repurposed medicines.
Real-world case studies
Hear from national and international initiatives through interactive case studies, successful public-private partnerships and cutting-edge clinical trials for rare disease.
Who is it for?
CONFERENCE AGENDA
Follow your track
Explore our agenda packed with talks, real-world case studies, and collaborative discussions across four dynamic tracks. See how experts are accelerating discoveries, reshaping development models, and bringing change to patients faster than ever.
View the full agenda here!
AI for drug repurposing
Innovative clinical trial designs
Repurposing for the under-served
Pathways to patient access
TICKETING
There are four different ticket types for this conference. If you are unsure of your ticket group, please email conference@remedi4all.org.
General Admission Ticket
Common ticket. Unless you belong to one of the groups listed below, this is the ticket you should select.
€450
€590
Special Early Bird ticket price
Small & Medium Enterprises (SMEs)
This ticket is reserved for Small & Medium Enterprises (SMEs) and other related enterprises .
€390
€450
Special Early Bird ticket price
Academia, Clinicians & Regulatory
This ticket is reserved for clinicians, academics, scientists, HTAs, regulatory and government bodies.
€230
€320
Special Early Bird ticket price
Patients & Charities Ticket
This ticket is reserved for patient organisations, patients, patient caregivers, and charities.
€90
€120
Special Early Bird ticket price
We are here to help
We appreciate there may be a financial-barrier to small patient groups and patients in attending this conference. We are able to offer support towards accommodation and travel costs and local transportation for these individuals. Please get in touch with conference@remedi4all.org to discuss your needs.
Payment policy
Payment policy: Payment can be made via Eventbrite or via bank transfer. Full invoices are available upon request. Contact conference@remedi4all.org for further details on payment and invoices.
Please note: our ticketing provider, Eventbrite, has introduced a new feature that allows you to reserve tickets before completing the order form which appears on the next page. To secure your tickets fully, please make sure to complete the form in its entirety.
Cancellation policy
Cancellation policy: All cancellations must be received in writing to conference@remedi4all.org 21 calendar days prior to the start of the event (16th April 2025). Eventbrite’s ticketing fee is non-refundable.
For cancellation after this time – or if the delegate fails to attend the event, no refund may be expected. Substitutions are welcome at no extra charge up until 1st May 2025.
The organisers reserve the right to cancel the event at any time without liability. In these circumstances, delegates will be offered an alternative date, a credit note, or a full refund.
Share your ideas
Be part of iDR26 at our Conference Poster Session, Lightening Talks and more — a dynamic platform for researchers, patient groups, and industry professionals to showcase their discoveries, insights, and innovations in drug repurposing. Connect with global experts, gain recognition, and compete for our Poster Prize! Highlight your work across categories such as patient-centric research, innovative methods, collaborations, and more.
Submit your idea!
Venue
Maison de la Poste
The international drug repurposing conference “Navigating the future” will take place at Maison de la Poste (Brussel) between 12-13 May 2026.
A site at the intersection of roads, bustling with economic activity: is there a better place to hold your conference or meeting? During the 16th and 17th century, the site served as pasture for the horses of the Von Thurn und Taxis family, who are credited with inventing the postal system. A truly inspiring place, decorated by international top designers.
Maison de la Poste
7 Rue Picard
1000 Bruxelles
Belgium
Accessibility Features
- Front entrance with steps – a ramp can be made available for step-free access
- Step-free back entrance
- Elevator access to all floors, except the tower room which is only accessible by stairs
- Tactile markers on the floors
- Quiet room with a restroom for nursing mothers/sensory breaks
- Disabled restroom on the ground floor with adjustable support railings
- Pump-style soap dispensers in restroom
- Sinks with touchless, automatic sensors to start water flow in restroom
- Hand dryers with touchless, automatic sensors in restroom
10 minutes on foot from Station Brussel Noord
Brussel Noord
Bus R50, R60, 14
Bus stop | Picard
15 minutes by car from Brussels Airport
Brussel Airport
Stay in one of the many hotels nearby
Co-organisers
REMEDi4ALL
REMEDi4ALL is an EU-funded research initiative that is driving forward the repurposing of medicines in Europe.
Beacon for rare diseases
Beacon is a UK-based charity that is building a united rare disease community with patient groups at its heart.
Headline Sponsor
ZonMw
ZonMw is the Dutch governmental organisation which programmes and funds research and innovation in health, healthcare, and well-being, encourages the use of this knowledge and highlights knowledge needs. ZonMw has been funding Drug Repurposing research for more than 10 years and has a dedicated funding call for Drug Repurposing.
ZonMw is leading a work package in REMEDi4ALL that aims to improve the funding landscape and to create innovative funding models. As part of this ZonMw has established the REMEDi4ALL Funders Network, a network of diverse funders passionate about drug repurposing to share best funding practices, co-ordinate (new) funding streams, promote joint calls, develop innovative co-funding models and discuss policy issues and possible solutions.
Platinum Sponsor
Chan Zuckerberg Initiative
The Chan Zuckerberg Initiative was founded in 2015 to help solve some of society’s toughest challenges — from eradicating disease and improving education, to addressing the needs of our local communities. Our mission is to build a better future for everyone.
Dompé farmaceutici S.p.A.
Dompé farmaceutici S.p.A., parent company of the Dompé operating companies, with headquarters in Milan, Italy and wholly-owned by the Italian company, Dompé Holdings srl, is an international biopharmaceutical company involved in all activities of the pharmaceutical value chain, from research to development, production and marketing. Our evolution has taken us from being Milan’s first compounding pharmacy to an international company that straddles both primary care and biopharma. As a long-established family company, we blend the stability that comes from our 130-year heritage with the agility and dynamism of a start-up.
Gold Sponsor
LifeArc
LifeArc is a not-for-profit medical research organisation; we turn promising scientific research into impact for people living with rare diseases and areas of global health.
We form partnerships, and provide scientific expertise and funding to help break down the barriers preventing scientific breakthroughs from becoming life-transforming treatments and cures. We have been doing this for more than 30 years and our work has resulted in five licensed medicines, including cancer drug pembrolizumab (Keytruda®) and lecanemab for Alzheimer’s (Leqembi®).
Our goal is a world where no one with a rare disease misses out on life-changing innovation because of complexity, cost or risk.
Sponsorship opportunities
Interested in becoming a sponsor of this event?
Showcase your business to a diverse audience, including researchers, the patient community, funders, regulators, and representatives from the private sector. As a sponsor, you'll get unique visibility through strategic logo placements, exhibition space, social media exposure, networking opportunities, and more. Contact our sponsorship team at sponsorship@remedi4all.org to find out more about the various sponsorship packages available.
Contact sponsorship teamREMEDi4ALL Partners & Associated partners
Interested in joining this event? Subscribe to the newsletter
We will keep you updated on the event. You can unsubscribe at any time.
